Does saw palmetto cause gynaecomastia? This is a question raised with increasing frequency among men using the herbal supplement for prostate enlargement or hair loss. Saw palmetto (Serenoa repens) is widely available in the UK as a food supplement or traditional herbal remedy, and its proposed mechanism — inhibiting the enzyme 5-alpha reductase — shares similarities with licensed medicines known to cause breast tissue changes in men. This article examines the evidence, explains the biological plausibility, outlines when to seek medical advice, and highlights NICE-aligned alternatives for the conditions saw palmetto is commonly used to treat.

What Is Saw Palmetto and How Is It Used in the UK?

Saw palmetto is sold in the UK primarily as an unregulated food supplement for benign prostatic hyperplasia and hair loss, with NICE guidance advising against its use for lower urinary tract symptoms due to insufficient clinical evidence.

Saw palmetto (Serenoa repens) is a small palm plant native to the southeastern United States. Its berries have been used for centuries in traditional medicine, and today the plant extract is widely available in the UK. It is most commonly marketed for the management of benign prostatic hyperplasia (BPH) — a non-cancerous enlargement of the prostate gland — and is also promoted for hair loss (androgenetic alopecia) and urinary symptoms in men.

In the UK, saw palmetto products are sold under two distinct regulatory categories, and it is important not to conflate them:

• Food supplements: The majority of saw palmetto products are sold as food supplements, regulated under UK food law. They are not assessed by the Medicines and Healthcare products Regulatory Agency (MHRA) for efficacy or safety before being placed on the market, and they cannot legally make medicinal claims.

• Traditional Herbal Registration (THR): Some saw palmetto products hold an MHRA THR, which means they have been assessed for quality and safety. Efficacy for THR products is accepted on the basis of traditional use rather than clinical trial evidence.

The proposed mechanism of action involves inhibition of 5-alpha reductase, the enzyme responsible for converting testosterone into dihydrotestosterone (DHT). However, this mechanism is largely based on in vitro (laboratory) data and should be regarded as theoretical in the context of human use. The degree of 5-alpha reductase inhibition varies considerably depending on the extract type, dose, and standardisation of the product — effects are generally weaker and less consistent than those of licensed pharmaceutical 5-alpha reductase inhibitors (5ARIs).

NICE guidance (CG97: Lower urinary tract symptoms in men) explicitly states that Serenoa repens should not be offered for the management of lower urinary tract symptoms (LUTS) or BPH, reflecting the lack of consistent clinical evidence for its efficacy (supported by Cochrane systematic review evidence). Men considering this supplement should discuss it with their GP or a pharmacist before starting, particularly if they are taking other medications or have underlying health conditions.

Understanding Gynaecomastia: Causes and Risk Factors

Gynaecomastia is benign male glandular breast enlargement caused by an imbalance between oestrogen and androgen activity, with common causes including medications, recreational drugs, and underlying medical conditions.

Gynaecomastia refers to the benign enlargement of glandular breast tissue in males, resulting from an imbalance between oestrogen and androgen activity in breast tissue. It is distinct from pseudogynaecomastia, which involves fatty tissue accumulation without true glandular proliferation. Gynaecomastia can affect one or both breasts and may present with tenderness or a palpable disc of tissue beneath the nipple.

The condition is relatively common across all age groups. Physiological gynaecomastia occurs in:

• Neonates (due to maternal oestrogen exposure)

• Adolescents (during puberty, when hormonal fluctuations are normal)

• Older men (as testosterone levels naturally decline with age)

Beyond physiological causes, a range of factors can contribute to pathological gynaecomastia, including:

• Medications — particularly anti-androgens (e.g., bicalutamide, cyproterone acetate), 5-alpha reductase inhibitors (e.g., finasteride, dutasteride), spironolactone, digoxin, ketoconazole, proton pump inhibitors, some antihypertensives, and certain antiretrovirals

• Recreational drugs — including cannabis, alcohol, and anabolic steroids

• Medical conditions — such as hypogonadism, hyperthyroidism, liver cirrhosis, and renal failure

• Tumours — including testicular, adrenal, or pituitary tumours that alter hormone production

The underlying mechanism in most cases involves either an increase in oestrogen activity, a decrease in androgen activity, or an alteration in the oestrogen-to-androgen ratio at the level of breast tissue receptors. Understanding these pathways is essential when evaluating whether any supplement — including saw palmetto — could plausibly contribute to breast tissue changes in men.

Further information is available via the NHS gynaecomastia page and NICE Clinical Knowledge Summary (CKS): Gynaecomastia.

Evidence Linking Saw Palmetto to Gynaecomastia

No robust clinical evidence establishes a definitive causal link between saw palmetto and gynaecomastia, though isolated case reports and its theoretical 5-alpha reductase inhibiting mechanism mean the possibility cannot be fully excluded.

The question of whether saw palmetto causes gynaecomastia arises with some regularity, particularly among men using the supplement for prostate or hair loss concerns. The short answer is that there is no robust clinical evidence establishing a definitive causal link, but the theoretical basis for concern is not entirely without foundation.

Because saw palmetto is proposed to inhibit 5-alpha reductase, it may reduce the conversion of testosterone to DHT. This mechanism is shared with pharmaceutical 5ARIs such as finasteride and dutasteride, both of which carry a recognised — though relatively uncommon — risk of gynaecomastia as a listed adverse reaction in their Summary of Product Characteristics (SmPC) on the Electronic Medicines Compendium (EMC). By analogy, it is biologically plausible that saw palmetto could produce a similar hormonal shift. However, it is important to emphasise that the potency and systemic hormonal effects of saw palmetto are considerably weaker and more variable than those of licensed 5ARIs, and differ substantially between products depending on extract type, dose, and standardisation.

A small number of case reports in the peer-reviewed medical literature have described gynaecomastia in men using saw palmetto, but case reports represent the lowest tier of clinical evidence and cannot establish causation. No large-scale randomised controlled trials have specifically investigated gynaecomastia as an outcome of saw palmetto use. It is also worth noting that many men who use saw palmetto are in age groups where physiological gynaecomastia is more prevalent, making attribution difficult.

Neither the MHRA nor the EMA/HMPC (in the Community herbal monograph on Sabal serrulata fruit) has issued a specific regulatory warning linking saw palmetto to gynaecomastia. Nevertheless, the pharmacological mechanism and isolated case reports suggest the possibility cannot be entirely dismissed.

Men who notice breast changes whilst taking saw palmetto should not assume the supplement is the cause, but should seek prompt medical evaluation. Suspected adverse reactions to herbal products and supplements can be reported via the MHRA Yellow Card scheme at https://yellowcard.mhra.gov.uk.

When to Seek Medical Advice About Breast Tissue Changes

Any new or unexplained breast change in a male should prompt urgent GP assessment; NICE NG12 recommends a two-week wait referral for men aged 30 and over with an unexplained breast lump.

Any new or unexplained change in breast tissue in a male patient warrants prompt medical assessment, regardless of whether a supplement or medication is being taken. While gynaecomastia is most often benign, it is important to rule out serious underlying causes, including male breast cancer, which — although rare — accounts for approximately 1% of all breast cancer diagnoses in the UK according to NHS data.

You should contact your GP if you notice:

• A new lump or swelling in one or both breasts

• Tenderness, pain, or sensitivity in the breast area

• Changes to the nipple, including discharge, inversion, or skin changes

• Breast enlargement that is rapidly progressing or asymmetrical

• Any breast change accompanied by other symptoms such as testicular swelling, fatigue, or unexplained weight loss

Urgent referral: In line with NICE guidance (NG12: Suspected cancer — recognition and referral), GPs should consider an urgent two-week wait referral for people aged 30 and over with an unexplained breast lump (with or without pain), or breast skin changes that could suggest cancer. For those under 30 with an unexplained breast lump, a non-urgent referral should be considered. If you are concerned about a breast change, do not delay in contacting your GP.

Your GP will typically take a thorough history — including all medications, supplements, and recreational drug use — and may arrange blood tests to assess hormone levels. A baseline investigation panel may include: testosterone, LH, FSH, oestradiol, prolactin, thyroid function (TFTs), beta-hCG, liver function (LFTs), and renal function (U&Es). A testicular examination should be performed, and testicular ultrasound considered if indicated. Breast ultrasound may also be requested, and in some cases referral to an endocrinologist or a breast clinic may be appropriate.

It is important to inform your GP about all supplements you are taking, including herbal products such as saw palmetto. Many patients do not consider supplements relevant to their medical history, but they can interact with medications and influence hormone levels. Stopping the supplement may be recommended as a first step if it is considered a possible contributing factor, and your GP can advise on this safely.

See also: NICE CKS: Gynaecomastia; NHS: Breast cancer in men.

Safer Alternatives and Guidance From UK Health Professionals

NICE-recommended treatments for BPH include alpha-blockers and 5-alpha reductase inhibitors, while licensed minoxidil and finasteride are preferred over saw palmetto for male pattern hair loss.

For men seeking evidence-based management of the conditions for which saw palmetto is commonly used, there are several NICE-aligned options worth discussing with a healthcare professional.

For benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS): NICE guidance (CG97: Lower urinary tract symptoms in men: management) recommends a stepwise approach beginning with lifestyle modifications (such as reducing evening fluid intake and bladder training), followed by licensed pharmacological treatments where appropriate. These include:

• Alpha-blockers (e.g., tamsulosin) — to relax smooth muscle in the prostate and bladder neck; first-line for voiding symptoms

• 5-alpha reductase inhibitors (e.g., finasteride) — for men with significantly enlarged prostates, though these carry their own hormonal side effects including, rarely, gynaecomastia

• Combination therapy (alpha-blocker plus 5ARI) in selected cases

• Antimuscarinics or mirabegron — for men with predominant storage (overactive bladder) symptoms

• Tadalafil — may be considered in selected men with LUTS

• Surgical or minimally invasive options — when pharmacological management is insufficient or not tolerated; referral to urology is appropriate in such cases

NICE CG97 explicitly states that Serenoa repens should not be offered for LUTS or BPH, reflecting the absence of consistent clinical evidence for its efficacy.

For androgenetic alopecia (male pattern hair loss): Licensed options include topical minoxidil (available over the counter) and oral finasteride 1 mg (available on prescription only). Both have a more established evidence base than saw palmetto, though finasteride again carries a small risk of hormonal side effects including gynaecomastia. Further information is available via NICE CKS: Androgenetic alopecia (male pattern hair loss).

From a patient safety perspective, UK health professionals generally advise caution with unregulated herbal supplements, particularly those with hormonal mechanisms of action. If you suspect an adverse reaction to a supplement or herbal product, you can report it via the MHRA Yellow Card scheme at https://yellowcard.mhra.gov.uk.

Ultimately, the best course of action is to discuss any supplement use openly with your GP or pharmacist, who can help weigh the potential benefits against the risks in the context of your individual health profile. Self-medicating with herbal products that influence hormone pathways carries inherent uncertainties, and professional guidance ensures that any treatment — conventional or complementary — is both safe and appropriate.

Key references: NICE CG97; NICE CKS: LUTS in men; BNF: Benign prostatic hyperplasia; NICE CKS: Androgenetic alopecia; EMC SmPCs for finasteride and minoxidil.

Frequently Asked Questions